• Osteopore records revenue of AUD 812K in Q3 CY25, up 7% YoY
• Secures market approval in Switzerland under EU MDR clearance
• Zimmer Biomet sales unit grows 3x in first 12 months of partnership

Osteopore Ltd (ASX:OSX), a manufacturer of regenerative implants, has released its quarterly results and Appendix 4C Quarterly Cash Flow Report for the three months ended 30 September 2025. The company recorded revenue of AUD 812K (SGD 682K) in Q3 CY25, representing a 7% year-on-year growth. Despite quarterly moderation, Osteopore's revenue continues to grow on a year-on-year basis. The company secured market access to Switzerland under the European Medical Device Regulation (EU MDR) clearance to supply its custom orthopaedic and cranial implants. This approval follows Osteopore's successful transition to MDR in 2023 and its partnership with Zimmer Biomet (NYSE and SIX: ZBH) in 2024. In the first 12 months of the Zimmer Biomet partnership (2024 H2 to 2025 H1), the number of implants sold from Europe, Australia, and Hong Kong grew three-fold compared to the 12 months prior (2023 H2 to 2024 H1). Osteopore also won tender bids in Vietnam, gaining entry into two major public hospitals for its orthopaedic products, including its centrepiece product for high tibial osteotomy (HTO) and other bone grafting applications.

Osteopore records revenue of AUD 812K (SGD 682K) in Q3 CY25, representing a 7% year-on-year growth.